On September 2, 2026 Caris Life Sciences (NASDAQ: CAI), a leading TechBio company, reported that researchers from Caris and the Caris Precision Oncology Alliance (Caris POA) will present seven studies at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), taking place September 12-15, 2026, in Seoul, South Korea. Caris research includes two mini oral presentations, one Poster Tour presentation and four poster presentations highlighting how comprehensive molecular profiling and AI-driven clinico-genomic analyses are advancing understanding of lung cancer biology, immunotherapy response and precision treatment strategies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This year’s presentations underscore the power of large-scale molecular and clinico-genomic datasets in revealing meaningful insights into cancer biology and therapeutic response," said George W. Sledge, Jr., M.D., Chief Medical Officer of Caris Life Sciences. "From immunotherapy biomarkers and tumor microenvironment analyses to germline testing and targeted therapy outcomes, these findings demonstrate how comprehensive molecular profiling can help inform clinical decision-making and accelerate the future of precision oncology."

Among the highlights are two mini oral presentations evaluating the impact of molecular and immune biomarkers in non-small cell lung cancer (NSCLC), a Poster Tour presentation examining transcriptomic subtypes in mesothelioma, and multiple studies leveraging the Caris clinico-genomic database to characterize genomic alterations, germline variants and treatment outcomes across thoracic malignancies.

Mini Oral Presentations:
Impact of Protein Arginine Methyltransferase 5 (PRMT5) Expression and MTAP Deletion on Overall Survival and Immune Cells in NSCLC
Session: MO05 – Evolving Pathological Grading and Molecular Profiling for Lung Cancer Risk Stratification and Treatment | Presentation: MO05.09
Monday, September 14, 2026 | 12:58 PM – 1:03 PM KST
Key Findings

Analysis of 39,124 NSCLC samples found that MTAP-deleted tumors demonstrated higher PRMT5 expression.
PRMT5-high/MTAP-deleted tumors were associated with the shortest overall survival across molecular subtypes.
Among patients treated with immune checkpoint inhibitors, PRMT5-high/MTAP-deleted tumors were associated with shorter overall survival than PRMT5-high/MTAP-non-deleted tumors.
PRMT5-high/MTAP-deleted tumors exhibited fewer CD8+ T-cells and other adaptive immune cells, suggesting a less favorable immune microenvironment.
Prevalence of Immunotherapy (IO) Biomarkers, Tumor Microenvironment (TME) Composition and Survival by Race/Ethnicity in NSCLC
Session: MO13 – Global Challenges and Solutions in Lung Cancer Management | Presentation: MO13.09
Tuesday, September 15, 2026 | 11:58 AM – 12:03 PM KST
Key Findings

Evaluation of 43,261 NSCLC samples identified race- and ethnicity-associated differences in tumor genomics, immune microenvironment composition and clinical outcomes.
Non-Hispanic Asian Pacific Islander patients demonstrated longer overall survival and fewer genomic alterations associated with resistance to immunotherapy than non-Hispanic White patients.
Among immunotherapy-treated patients, non-Hispanic Black patients achieved longer survival despite a higher prevalence of immunotherapy-resistance molecular alterations.
Poster Tour:
Transcriptomic Subtypes Predict Frontline Therapy Response in Pleural (MPM) and Peritoneal Mesothelioma (MPeM)
Session: PT2.05 – Mesothelioma, Thymoma, and Other Thoracic Tumors | Presentation: PT2.05.03
Monday, September 14, 2026 | 2:01 PM – 2:09 PM KST
Key Findings

Transcriptomic analysis of 386 mesothelioma samples identified three biologically distinct clusters with unique molecular features and treatment outcomes.
Chemotherapy, with or without bevacizumab, was associated with longer overall survival than immune checkpoint inhibitor therapy in two of the three clusters.
If validated prospectively, the identified transcriptomic subtypes could help inform therapeutic decision-making and support a more personalized treatment approach for mesothelioma.
Posters Include:
Prevalence and Spectrum of Germline Variants in Non-Small Cell Lung Cancer: Insights from a Large-Scale CARIS Analysis | Presentation: P2.097

Clinically relevant germline alterations were identified in 12.2% of 3,609 NSCLC patients.
Frequently altered genes included MUTYH, CHEK2, ATM, BRCA2 and MITF.
Among patients with linked tumor profiling, 45.8% of pathogenic, likely pathogenic or risk germline variants had a matching tumor variant.
Germline Alterations in Small Cell Lung Cancer Identified Through Blood-Based Profiling | Presentation: P2.098

Clinically relevant germline alterations were identified in 13.4% of 149 small cell lung cancer patients with germline findings.
Common alterations included MUTYH, APC, ATM, BRIP1 and CHEK2.
In patients with linked tumor sequencing, more than half of pathogenic, likely pathogenic or risk germline variants had corresponding tumor variants.
Clinico-Biological Characteristics and Treatment Outcomes in Patients With RET+ Lung Cancer with Non-LUAD Histology | Presentation: P2.102

Among 588 RET-positive patients in the RET-MAP registry, 45 patients, or 7.7%, had non-lung adenocarcinoma (LUAD) histology.
Non-LUAD histology was independently associated with shorter progression-free and overall survival following both selective RET inhibitors and first-line chemotherapy.
Patients with large cell neuroendocrine carcinoma demonstrated a 75% objective response rate encouraging responses to selective RET inhibitors, with survival outcomes comparable to LUAD.
ITGB6 Expression and Real-World Outcomes in Non-Small Cell Lung Cancer | Presentation: P3.252

Analysis of 34,022 NSCLC samples demonstrated that ITGB6 expression varies by histology and genomic context.
High ITGB6 expression was associated with improved overall survival in lung adenocarcinoma but poorer outcomes in lung squamous cell carcinoma.
These opposing prognostic associations support further evaluation of ITGB6 across molecularly defined NSCLC populations.
Research highlights will be available at Caris’ booth #813. The full abstracts are available on the Caris website.

(Press release, Caris Life Sciences, SEP 2, 2026, View Source [SID1234670551])